Figure 2
From: Adding pharmacogenomics to the development of new marine-derived anticancer agents
Strategy of the proposed pharmacogenomic program of Yondelis™ in sarcoma patients: Gene expression profiles of tumor samples from sarcoma patients treated with Yondelis will be retrospectively analyzed and correlated with their clinical outcome. The DNA repair capability will be analyzed in blood samples of the same patients in order to be used as surrogate marker of response. The putative correlation found between GEP and clinical outcome will be prospectively analyzed in sarcoma patients and further studied in other tumors.